Physician profile
Jerry Railey
NPI 1417008905
$465.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $114 · 2021: $192 · 2022: $35.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $214.79 | 2020-2022 | |
| Kaleo, INC. | $57.04 | 2019 | |
| Biodelivery Sciences International, INC. | $36.90 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $28.23 | 2019 | |
| Orthogenrx INC. | $20.84 | 2021 | |
| Grt US Holding, INC. | $18.86 | 2022 | |
| Ibsa Pharma INC. | $18.61 | 2021 | |
| Virtus Pharmaceuticals LLC | $16.10 | 2021 | |
| Abbvie INC. | $16.08 | 2021 | |
| Pacira Therapeutics, INC. | $13.89 | 2019 | |
| Nevro Corp. | $12.45 | 2019 | |
| Assertio Therapeutics, INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Railey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.